Patients must have measureable hepatic disease and/or presence of vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) which may not be measureable as per Response Evaluation Criteria in Solid Tumors (RECIST) on liver CT or MRI, within 28 days PRIOR TO STUDY ENTRY
Subject has progressive disease with at least one measureable lesion on MRI.
Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v1.1
Measureable disease as defined by the RECIST 1.1.
Measureable disease (defined as at least 1.5 cm in diameter).
Measureable disease per response evaluation criteria (RECIST) v1.1
For Part G, H, and I: Have measureable disease as defined by RECIST 1.1.
Patients enrolled in the expansion cohort must have at least one measureable lesion as defined by the RECIST 1.1 criteria
Has measureable disease by RECIST 1.1 criteria as assessed by the local site investigator/radiology.
Measureable or evaluable disease by RECIST v1.1 for solid tumors prior to the administration of study drug
Must have measureable disease as per RECIST Version 1.1 or RANO (for GBM).
Measureable disease according to RECIST Version 1.1
At least one measureable lesion as defined by RECIST version 1.1 that has not been previously irradiated
Measureable disease
Have measureable disease
At least one measureable tumor lesion that that has not been previously locally
Part 2 only: have measureable disease by RECIST
Measureable disease.
Measurable and/or non-measureable disease by RECIST criteria must be present
Patients with measureable or non-measureable disease are eligible
Measureable disease according to RECIST Version 1.1
Radiographically measureable disease.
Has measureable disease
Has measureable or nonmeasurable disease as defined by RECIST 1.1 criteria.
Subjects must have measureable disease according to RECIST (version 1.1).
Radiographically measureable disease
Radiographically measureable disease
Radiographically measureable disease
Measureable (target) disease.
At least one measureable lesion by RECIST 1.1.
Have measureable disease per RECIST 1.1.
Subjects must have measureable disease as defined by RECIST 1.1 criteria or modified RECIST criteria
Subjects who have brain metastasis as the only measureable lesion
At least one measureable lesion as defined by RECIST version 1.1 that has not been previously irradiated.
At least one measureable lesion.
Measureable disease
Measureable disease
Chemoembolization is allowed if >= 4 weeks from study entry; there are 3 possible scenarios:\r\n* If patient has hepatic disease only: they need to have progressed in the liver since chemoembolization and have measureable disease by RECIST 1.1 in order to be eligible\r\n* If patient has hepatic and extrahepatic disease: they will need to have progressed inside OR outside the liver and have measureable disease by RECIST 1.1 in order to be eligible
Measureable disease according to RECIST Version 1.1
Presence of measureable disease based on RECIST v1.1
Subjects must have at least 1 lesion that is measureable using RECIST guidelines
Measureable disease per RECIST v1.1 prior to administration of study medication
Tumors in previously irradiated fields may be considered measureable if there is evidence of tumor progression after radiation treatment.
Patients must have measureable or evaluable disease
Objective, measureable, symptomatic organ involvement, defined as one or more of the following:
Measureable disease as per RECIST
Presence of at least one measureable tumor lesion is required
Patients who have no measureable disease by serologic or urine markers (detectable disease only by bone marrow or imaging scans)
Women with >= 2 cm clinically or radiologically measureable breast cancer
Previously untreated participants must have a measureable lesion on an imaging study
Subject must have measureable disease by RECIST 1.1.
Presence of measureable disease based on RECIST v1.1.
Measureable disease
Presence of measureable disease based on RECIST v1.1
